Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure.

Jean-François KorobelnikAnat LoewensteinBora EldemAntonia M JoussenAdrian KohGeorge N LambrouPaolo LanzettaXiaoxin LiMonica Lövestam-AdrianRafael NavarroAnnabelle Ayame OkadaIan PearceFrancisco J RodríguezDavid T WongLihteh Wu

Published in: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2021)

Consistency in monitoring of local infection rates and adjustment of clinical practice accordingly will be required as we move forward through the COVID-19 era. Ophthalmologists must continue to carefully weigh the risk-benefits to minimize the exposure of patients and healthcare staff to COVID-19, ensure that patients receive sight-saving treatment, and avoid the potential long-term impact of prolonged treatment postponement.

Keyphrases

coronavirus disease
end stage renal disease
sars cov
healthcare
chronic kidney disease
ejection fraction
newly diagnosed
clinical practice
prognostic factors
vascular endothelial growth factor
endothelial cells
respiratory syndrome coronavirus
patient reported outcomes
health information
platelet rich plasma